PUMA BIOTECHNOLOGY, INC. — Investor Relations & Filings
Filings indexed
1,055
across all filing types
Latest filing
2026-05-07
Regulatory Filings
Country
US
United States of America
Listing
US
PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. The company's primary commercial product is Nerlynx® (neratinib), an FDA-approved oral medication for certain types of breast cancer. Its clinical pipeline includes alisertib, an investigational drug being evaluated in clinical trials for small cell lung cancer and metastatic breast cancer. The company's mission is to develop and commercialize innovative products to enhance cancer care.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-05-07 | English | |
| ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-04-28 | English | |
| SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject) | 2026-03-27 | English | |
| 10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | |
| 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | |
| 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 43531573 | 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-05-07 | English | ||
| 38160772 | ARS - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-04-28 | English | ||
| 33062747 | SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject) | 2026-03-27 | English | ||
| 32891304 | 10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | ||
| 32891296 | 8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer) | 2026-02-26 | English | ||
| 32700165 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 32700155 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 32700152 | 4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer) | 2026-02-21 | English | ||
| 29414787 | 4 Filing | 2026-01-08 | English | ||
| 29414786 | 4 Filing | 2026-01-08 | English | ||
| 29414770 | 4 Filing | 2026-01-08 | English | ||
|
2025
4 filings
| |||||
| 12162691 | FORM 4 | 2025-11-13 | English | ||
| 12162694 | Regulatory Filings 2025 | 2025-11-12 | English | ||
| 12162697 | FORM 10-Q | 2025-11-06 | English | ||
| 12162702 | FORM 8-K | 2025-11-06 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
PUMA BIOTECHNOLOGY, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33488/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33488 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33488 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33488 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33488}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PUMA BIOTECHNOLOGY, INC. (id: 33488)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.